Diabetes

British Medical Bulletin

Volumn 59, Issue , 2001, Pages 159-172

  Timmis, Adam D ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABCIXIMAB; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; STATIN; THROMBOCYTE SLOWING FACTOR; THROMBOXANE A2; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

AUTONOMIC NEUROPATHY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG INDICATION; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SMOKING CESSATION; SUDDEN DEATH;

ANGINA PECTORIS; ARTERIOSCLEROSIS; BLOOD GLUCOSE; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DIABETIC ANGIOPATHIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INSULIN; LIPIDS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RISK; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 0035689403     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/59.1.159     Document Type: Review

References (93)

1. Atherogenesis in diabetes
2. Diabetes and cardiovascular risk factors: The Framingham Study
3. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
4. Advanced glycation end products, oxidant stress and vascular lesions
5. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose
6. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
7. Role of insulin resistance in human disease
8. Cardiovascular risk continuum: Implications of insulin resistance and diabetes
9. Is insulin really a heart disease risk factor?
10. Insulin and risk of cardiovascular disease: A meta-analysis
11. Insulin sensitivity and atherosclerosis
12. Diabetic dyslipidemia
13. Diabetes, hyperlipidemia, and coronary artery disease
14. Lipid modification and coronary heart disease in type 2 diabetes: Different from the general population
15. In vivo formation of 8-iso-prostaglandin F2a and platelet activation in diabetes mellitus: Effects of improved metabolic control
16. The effects of type 1 diabetes mellitus on the gender differences in coronary artery calcification
17. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study
18. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
19. HDS 1: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications
20. HDS 2: Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients
21. Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS 23)
22. Diabetic retinopathy at diagnosis of type 2 diabetes associated risk factors (UKPDS 30)
23. Tight blood pressure control and risks of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
24. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension optimal treatment (HOT) randomised trial
25. Joint British recommendations on prevention of coronary heart disease in clinical practice
26. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
27. Effect of antihypertensive therapy on the kidneys in patients with diabetes: A meta-regression analysis
28. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39)
29. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
30. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
31. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
32. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
33. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
34. Hyperglycemia and microvascular and macrovascular disease in diabetes
35. The association of glycemia and cause-specific mortality in a diabetic population
36. The effects of improved glycemic control on complications in type 2 diabetes
37. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
38. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35)
39. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus
40. Pathogenesis of the insulin resistance syndrome (syndrome X)
41. Collaborative overview of randomised trials of randomised trials of antiplatelet therapy. 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
42. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy
43. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidaemic rabbit
44. Effects of captopril on atherosclerosis in Cynomolgus monkeys
45. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structures, and wall rheology in the hindquarters of atherosclerotic mini-pigs
46. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients widh cobonary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study
47. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
48. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Result of HOPE study and MICRO-HOPE substudy
49. Coronary disease among United States soldiers killed in action in Korea: Preliminary report
50. Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth
51. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
52. Compensatory enlargement of human atherosclerotic coronary arteries
53. Exertional myocardial ischemia in diabetes: A quantitative analysis of anginal perceptual threshold and the influence of autonomic function
54. Angina and exertional myocardial ischemia in diabetic and non-diabetic patients: Assessment by exercise thallium scintigraphy
55. Investigation of coronary artery disease in diabetes; is screening of asymptomatic patients necessary?
56. Screening for asymptomatic coronary artery disease in diabetes
57. Silent myocardial ischemia in patients with diabetes: Who to screen?
58. Prevalence of unrecognised silent myocardial ischemia and its association with atherosclerotic risk factors in non insulin-dependent diabetes mellitus
59. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects
60. Atherosclerotic vascular complications in diabetic transplant candidates
61. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: Assessment by dipyridamole thallium-201 scintigraphy
62. Preoperative strategies to assess cardiac risk before noncardiac surgery
63. Long-term survival of more than 2,000 patients after coronary artery bypass grafting
64. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus
65. Investigators comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
66. Attenuation or absence of circadian and seasonal rhythms of acute myocardial infarction
67. Acute myocardial infarction in the diabetic patient: Pathophysiology, clinical course and prognosis
68. Prognostic implications of ventricular fibrillation in acute myocardial infarction: New strategies required for further mortality reduction
69. Symptomatic myocardial infarction without chest pain: Prevalence and clinical course
70. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis
71. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents
72. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: Effects on mortality at 1 year
73. Effects of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients: A radionuclide ventriculographic study
74. Glucose and the metabolism of ischaemic myocardium
75. Diabetes and ischemic heart disease
76. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction retrospective data from two large studies
77. Cardiac denervation in diabetic neuropathy
78. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications
79. Prolonged QT period in diabetic autonomic neuropathy: A possible role in sudden cardiac death?
80. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients
81. Silent myocardial ischaemia: The role of subclinical neuropathy in patients with and without diabetes
82. Prolonged anginal perceptual threshold in diabetes: Effects on exercise capacity and myocardial ischemia
83. Myocardial infarction in diabetics
84. Role of diabetes in congestive heart failure: The Framingham study
85. New types of cardiomyopathy associated with diabetic glomerulosclerosis
86. The myocardial and vascular pathology of diabetic cardiomyopathy
87. Diabetic cardiomyopathy
88. Diabetes mellitus and congestive heart failure: Further knowledge needed
89. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
90. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
91. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus
92. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients